Osteoblasts modulate secretion of urokinase-type plasminogen activator (uPA) and matrix metalloproteinase-9 (MMP-9) in human prostate cancer cells promoting migration and matrigel invasion

Oncology Research

Volumn 11, Issue 1, 1999, Pages 17-31

  Festuccia, Claudio ^a   Giunciuglio, Daniela ^b   Guerra, Fulvio ^a   Villanova, Ida ^a   Angelucci, Adriano ^a   Manduca, Paola ^c   Teti, Anna ^a   Albini, Adriana ^b   Bologna, Mauro ^a  

^a UNIVERSITY OF L'AQUILA   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

^c UNIVERSITY OF GENOA   (Italy)

Author keywords

Bone metastasis; Metalloproteinase 9; Prostate cancer; Urokinase

Indexed keywords

COLLAGEN; COLLAGENASE; GELATINASE B; LAMININ; MATRIGEL; PROTEOGLYCAN; TUMOR PROTEIN; UROKINASE;

ARTICLE; CANCER INVASION; CELL CULTURE; CELL MOTION; CHEMOTAXIS; CULTURE MEDIUM; DRUG COMBINATION; DRUG EFFECT; HUMAN; MALE; METABOLISM; OSTEOBLAST; PATHOLOGY; PHYSIOLOGY; PROSTATE TUMOR; SECRETION;

CELL MOVEMENT; CHEMOTAXIS; COLLAGEN; COLLAGENASES; CULTURE MEDIA, CONDITIONED; CULTURE MEDIA, SERUM-FREE; DRUG COMBINATIONS; HUMANS; LAMININ; MALE; MATRIX METALLOPROTEINASE 9; NEOPLASM INVASIVENESS; NEOPLASM PROTEINS; OSTEOBLASTS; PROSTATIC NEOPLASMS; PROTEOGLYCANS; TUMOR CELLS, CULTURED; URINARY PLASMINOGEN ACTIVATOR;

EID: 0032602538     PISSN: 09650407     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. Stringa, E.; Filanti. C.; Giunciuglio, D.; Albini, A.; Manduca, P. Osteoblastic cells from rat long bone: I - characterization of their differentiation in culture. Bone 95:663-670; 1995.
2. Magro, C.; Orr, F. W.; Manishen, W. J.; Sivanathan, K.; Mokashi, S. S. Adhesion, chemotaxis and aggregation of Walker carcinosarcoma cells in response to products of resorbing bone. J. Natl. Cancer Inst. 74:829-838; 1985.
3. Giunciuglio, D.; Cai, T.; Filanti, C.; Manduca, P.; Albini, A. Effect of osteoblast supernatants on cancer cell migration and invasion. Cancer Lett. 97:69-74; 1995.
4. Ritchie, C. K.; Andrews, L. R.; Thomas, K. G.; Tindall, D. J.; Fitzpatrick, L. A. The effects of growth factors associated with osteoblasts on prostate carcinoma proliferation and chemotaxis: Implication for the development of metastatic disease. Endocrinology 138:1145-1150; 1997.
5. Shevrin, D. H.; Gorny, K. I.; Rosol, T. J.; Kukreja, S. C. Effect of etidronate disodium on the development of bone lesions in an animal model of bone metastasis using the human prostate cancer cell line PC-3. Prostate 19:149-154; 1991.
6. Sasaki, A.; Boyce, B. F.; Story, B.; Wright, K. R.; Chapman, M.; Boyce, R.; Mundy, G. R.; Yoneda, T. Bisphosphonate risedronate reduces metastatic human breast cancer burden in bone in nude mice. Cancer Res. 55:3551-3557; 1995.
7. Mignatti, P. E.; Robbins, E.; Rifkin, D. B. Tumor invasion through the amniotic membrane: Requirement for a proteolytic cascade. Cell 47:111-120; 1986.
8. Cottam, D. W.; Rees, R. C. Regulation of matrimetalloproteinases: Their role in tumor invasion and metastasis. Int. J. Oncol. 2:861-872; 1993.
9. Danø, K.; Andreasen, P. A.; Grondahl-Hansen, J.; Kristiansen, P.; Nielsen, L. S.; Skrivers, L. Plasminogen activators, tissue degradation and cancer. Adv. Cancer Res. 44:139-266; 1985.
10. Stahl, A.; Muller, B. M. Binding of urokinase to its receptor promotes migration and invasion of human melanoma cells in vitro. Cancer Res. 54:3066-3071; 1994.
11. Liotta, L. A.; Stetler-Stevenson, W. G. Tumor invasion and metastasis an imbalance of positive and negative regulation. Cancer Res. (Suppl.) 51:5054S-5059S; 1991.
12. Hienert, G.; Kirchheimer, J. C.; Pfluger, H.; Binder, B. R. Urokinase-type plasminogen activator as a marker for the formation of distant metastases in prostatic carcinoma. J. Urol. 140:1466-1469;1988.
13. Koutsillieris, M.; Frenette, G.; Lazure, C.; Lehoux, J. G.; Govidan, M. W.; Polychronakos, C. Urokinase-type plasminogen activator: A paracrine factor regulating the bioavailability of IGFs in PA-III cell-induced osteoblastic metastases. Anticancer Res. 13:481-486;1993.
14. Lyon, P. B.; See, W. A.; Xu, Y.; Cohen, M. B. Diversity and modulation of plamsinogen activator activity in human prostate carcinoma cell lines. Prostate 27:179-186; 1995.
15. Festuccia, C.; Vicentini, C.; Di Pasquale, A. B.; Aceto, G.; Zaz-zeroni, F.; Miano, L.; Bologna, M. Plasminogen activator activities in short term tissue cultures of benign prostatic hyperplasia and prostatic carcinoma. Oncol. Res. 7:131-138; 1995.
16. Festuccia, C.; Dolo, V.; Guerra, F.; Violini, S.; Muzi, P.; Pavan, A.; Bologna, M. Plasminogen activator system modulates invasive capabilities and cell proliferation in prostatic tumor cells. Clin. Exp. Methods 16:513-528; 1998.
17. Hamdy, F. C.; Cottam, D. W.; Rees, R. C.; Williams, J. L. Matrix metalloproteinase 9 expression in primary human prostatic adenocarcinoma and benign prostatic hyperplasia. Br. J. Cancer 69:177-182; 1994.
18. Festuccia, C.; Bologna, M.; Vicentini, C.; Tacconelli, A.; Miano, R.; Mackay, A. R. Increased matrix metalloproteinase-9 secretion in short-term tissue cultures of prostatic tumor cells. Int. J. Cancer 69:386-393; 1996.
19. Albini, A.; Iwamoto, Y.; Kleinman, H. K.; Martin, G. R.; Aaronson, S. A.; Kozloswki, J. N.; McEwan, R. N. A rapid in vitro assay for quantitating the invasive potential of tumor cells. Cancer Res 47:3239-3245; 1987.
20. Ellis, V.; Pyke, C.; Erikson, J.; Solberg, H.; Danø, K. The urokinase receptor: Involvement in cell surface proteolysis and cancer invasion. Ann. NY Acad. Sci. 667:3113-3127; 1992.
21. Andreasen, P. A.; Kjoller, L.; Christensen, L.; Duffy, M. J. The urokinase-type plasminogen activator system in cancer metastasis: A review. Int. J. Cancer 72:1-22; 1997.
22. Farina, A. R.; Tiberio, A.; Tacconelli, A.; Cappabianca, L.; Gulino, A.; Mackay, A. R. Identification of plasminogen in matrigel and its activation by reconstitution of this basement membrane extract. Biotechniques 21:904-909; 1996.
23. Festuccia, C.; Guerra, F.; D'Ascenzo, S.; Giunciuglio, D.; Albini, A.; Bologna, M. In vitro regulation of pericellular proteolysis in prostatic tumor cells treated with bombesin. Int. J. Cancer 75:418-431; 1998.
24. Haq, M.; Goltzman, D.; Trembly, G.; Brodt, P. Prostate adenocarcinoma cells disseminate to bone and preferentially to bone marrow derived endothelial cells. Cancer Res. 52:4613-4619; 1992.
25. Zelter, B. R. The cellular basis of site specific tumour metastasis. N. Engl. J. Med. 322:605-612; 1990.
26. Lang, S. H.; Miller, W. R.; Habib, F. K. Stimulation of human prostate cancer cell lines by factor present in human osteoblast-like cells but not in bone marrow. Prostate 27:287-293; 1995.
27. Festuccia, C.; Teti, A.; Bianco, P.; Guerra, F.; Vicentini, C.; Tennina, R.; Villanova, I.; Sciortino, G.; Bologna, M. Human prostatic tumor cells in culture produce growth and differentiation factors active on osteoblast: A new biological and clinical parameter for prostatic carcinoma. Oncol. Res. 9:419-431; 1997.
28. Manishen, W. J.; Sivanathan, K.; Orr, F. W. A role for the host microenvironment in bone metastasis. Am. J. Pathol. 123:34-45; 1986.
29. Liotta, L. A.; Mandler, D. L.; Murano, G.; Katz, D. A.; Gordon, R. K.; Chiang, P. K.; Schiffmann, E. Tumor cell autocrine motility factor. Proc. Natl. Acad. Sci. USA 83:3302-3306; 1986.
30. Naldini, L.; Tamagnone, L. Vigna, E.; Hartmann, G.; Bircheimer, W.; Daikuhara, Y.; Tsubuchi, H.; Blasi, F.; Comoglio, P.M. Extracellular proteolytic clevage by urokinase is required for activation of hepatocyte growth factor/scatter factor. EMBO J. 11:4825-4833; 1992.
31. Sanchez-Sweatman, O. H.; Lee, J.; Orr, F. W.; Singh, G. Direct osteolysis induced by metastatic murine melanoma cells: Role of matrix metalloproteinases. Eur. J. Cancer 33:918-925; 1997.
32. Angeloz-Nicoud, P.; Binoux, M. Autocrine regulation of cell proliferation by insulin-growth factor (IGF) and IGF binding protein-3 protease system in a human prostate carcinoma cell line (PC3). Endocrinology 136:5485-5492; 1995.
33. Conover, C. A.; Durham, S. K.; Zapf, J.; Masiarz, F. R.; Kiefer, M. C. Cleavage analysis of insulin-like growth factor (IGF)-dependent IGF-binding proteion 4 proteolysis and expression of protease resistant IGF-binding protein 4 mutants. J. Biol. Chem. 270: 4395-4400; 1995.
34. Morton, D. M.; Barrack, E. R. Modulation of transforming growth factor bl effects on prostate cancer cell proliferation by growth factors and extracellular matrix. Cancer Res. 55:2596-2602; 1995.
35. Kleiner, D. E.; Stetler-Stevenson, W. G. Quantitative zymography: Detection of picogram quantities of gelatinases. Anal. Biochem. 218:325-329; 1994.
36. Zucker, S.; Mancuso, P.; Dimassimo, B.; Lysik, R. M.; Conner, W. C. Comparision of techniques for measurement of gelatinase/ type IV collagenases: Enzyme-linked immunoassays versus substrate degradation assays. Clin. Exp. Metastasis 12:13-23; 1994.
37. Mackay, A. R.; Ballin, M.; Pelina, M. D.; Farina, A. R.; Nason, A. M.; Hartzler, J. L.; Thorgeirsson, U. P. Effect of phorbol ester and cytokines on matrix metalloproteinases and tissue inhibitor of metalloproteinase expression in tumor and normal cell lines. Invasion Metastasis 12:168-184; 1992.
38. Moll, U. M.; Younglaeb, G. L.; Rosinski, K. B.; Quigley, J. P. Tumor promoter-stimulated Mr92,000 type IV collagenase secreted by normal and malignant human cells; isolation and characterization of the enzyme from HT-1080 tumor cells. Cancer Res. 50:6162-6170; 1990.
39. Hanemaaijer, R.; Visser, H.; Kottinen, Y. T.; Koolwijk, P.; Verheijen, J. H. A novel and simple immunocapture assay for determination of gelatinase B (MMP-9) activities in biological fluids: Saliva from patients with Sjogren's syndrome contain increased latent and active gelatinase B levels. Matrix Biol. 17:657-665; 1998.
40. Cowell, S.; Knauper, V.; Stewart, M. L.; D'Ortho, M. P.; Stanton, H.; Hembry, R. M.; Lopez-Otin, C.; Reynolds, J. J.; Murphy, G. Induction of matrix metalloproteinase activation cascade based on membrane type 1 matrix metalloproteinase: Associated activation of gelatinase A, gelatinase B and collagenase 3. Biochem. J. 15: 453-458; 1998.
41. Makowski, G. S.; Ramby, M. L. binding of latent matrix metalloproteinase 9 to fibrin: Activation via a plasmin-dependent pathway. Inflammation 22:287-305; 1998.
42. Duncan, M. E.; Richardson, J. P.; Murray, G. I.; Melvin, W. T.; Fothergill, J. E. Human matrix metalloproteinase-9: Activation by limited trypsin treatment and generation of monoclonal antibodies specific for activated form. Eur. J. Biochem. 15:37-43; 1998.
43. Ingram, R.; Bonde, S.; Riggs, B. L.; Fitzpatrick, L. A. Effects of transforming growth factor β1 (TGF-β1) and 1,23 dihydrovitamin D3 on the function, cytochemistry and morphology of normal human osteoblast-like cells. Differentiation 55:153-163; 1994.
44. Gabbitas, B.; Pash, J.; Canalis, E. Regulation of insulin-like growth factor-II sysnthesis in bone cell cultures by skeletal growth factors. Endocrinology 135:284-289; 1994.
45. Ishimi, Y.; Miyaura, C.; Akatsu, T.; Abe, E.; Nakamura, Y.; Yamaguchi, A.; Yoshiki, S.; Matsuda, T.; Hirano, T. IL-6 is produced by osteoblasts and induces bone resorption. J. Immunol. 145:3297-3303; 1990.
46. Chaudhary, L. R.; Spelsberg, T. C.; Riggs, B. L. Production of various cytokines by normal human osteoblast-like cells in response to interleukin-β1 and TNF-α: Lack of regulation by 17 β estradiol. Endocrinology 130:2528-2534; 1992.
47. Festuccia, C.; Bologna, M.; Gravina, G. L.; Guerra, F.; Angelucci, A.; Villanova, I.; Millimaggi, D.; Teti, A. Osteoblast conditioned media contain TGF-β1 and modulate the migration and the interaction of prostate tumor cells with extracellular matrix components. Int. J. Cancer 81:395-103; 1999.
48. Farina, A. R.; Coppa, A.; Tiberio, A.; Tacconelli, A.; Colletta, G.; Gulino, A.; Mackay, A.R. Transforming growth factor b1 inhances the invasiveness of human MDA-MB-231 breast cancer cells by upregulating urokinase activity. Int. J. Cancer 75:721-730; 1998.